RIFA XISIGN 550 TAB is a high-efficacy gastrointestinal antibiotic formulation developed by Bluepill Express, incorporating Rifaximin 550 mg per tablet. Rifaximin is a non-systemic, semi-synthetic derivative of rifamycin with broad-spectrum antibacterial properties. It acts locally within the gastrointestinal tract to inhibit bacterial RNA synthesis, thereby reducing pathogenic bacteria while avoiding significant systemic absorption.

This pharmaceutical preparation is indicated for the treatment of various GI-related infections and conditions, including hepatic encephalopathy, traveler’s diarrhea caused by non-invasive strains of Escherichia coli, and irritable bowel syndrome with predominant diarrhea (IBS-D). The localized action of Rifaximin helps prevent neurotoxic buildup in patients with liver dysfunction by reducing ammonia-producing gut bacteria. In IBS-D, it improves symptoms such as bloating, gas, abdominal pain, and diarrhea. The 550 mg dosage strength is recommended for adults and is typically administered over a 14-day course or as advised by the physician depending on the clinical condition.

RIFA XISIGN 550 TAB is known for its minimal drug resistance potential and favorable safety profile. It is well tolerated even with prolonged usage in chronic liver disease cases. As the drug is minimally absorbed, the likelihood of systemic side effects is very low, making it a reliable choice for long-term gastrointestinal bacterial control. Occasional mild side effects may include abdominal discomfort or nausea, but these are transient and self-limiting in most cases.

Bluepill Express employs advanced manufacturing techniques, including wet granulation, precision compression, and film coating, to ensure dose uniformity, bioavailability, and shelf-life stability. Every batch of RIFA XISIGN 550 TAB undergoes strict in-process quality controls and final release testing to confirm its potency, purity, and compliance with pharmacopeial standards. The company adheres to global regulatory norms, including WHO-GMP, ISO 9001:2015, and is equipped to support clients with dossiers in CTD/ACTD formats for international regulatory submissions.

The product is available in alu-alu or blister packs that provide moisture and light protection, ensuring extended stability and consistent performance. It is designed to meet export specifications and comes with all relevant documentation including COA (Certificate of Analysis), stability data, manufacturing license, and COPP (Certificate of Pharmaceutical Product) where applicable.

Bluepill Express offers comprehensive third-party manufacturing solutions for RIFA XISIGN 550 TAB including private labeling, custom packaging, global shipping, and responsive after-sales support. Clients across the UK, USA, Africa, Latin America, and Southeast Asia rely on Bluepill Express for dependable antibiotic formulations that meet international benchmarks for safety, efficacy, and affordability.

RIFA XISIGN 550 TAB remains a crucial part of the therapeutic arsenal against serious and recurring gastrointestinal infections. Its broad-spectrum, non-systemic action makes it an ideal choice for patients requiring safe, effective, and locally acting antibacterial treatment. With its strong clinical utility and manufacturing excellence, this product continues to serve global healthcare needs through Bluepill Express's reliable and scalable production capabilities.